Suppr超能文献

精神分裂症患者的血小板单胺氧化酶活性。与疾病遗传负荷及抗精神病药物治疗的关系。

Platelet monoamine-oxidase activity in schizophrenia. Relation to genetic load of the illness and treatment with antipsychotic drugs.

作者信息

Kemali D, Maj M, Ariano M G, Salvati A

出版信息

Encephale. 1985 Jan-Feb;11(1):31-4.

PMID:2859981
Abstract

A significant decrease of mean platelet monoamine-oxidase (MAO) activity was observed in a sample of haloperidol-treated schizophrenic patients as compared with normal control subjects. The enzyme activity was not significantly reduced in drug-free schizophrenics. No significant difference was found between drug-free schizophrenics with and without a family history of the illness and between healthy relatives of schizophrenics and normal subjects without a family history of schizophrenia. MAO activity was significantly reduced after 14 and 21 days of treatment with haloperidol, in comparison with baseline values. It is suggested that neuroleptic intake may at least in part explain low MAO values repeatedly reported in schizophrenics.

摘要

与正常对照受试者相比,在一组接受氟哌啶醇治疗的精神分裂症患者样本中观察到平均血小板单胺氧化酶(MAO)活性显著降低。未服用药物的精神分裂症患者的酶活性没有显著降低。在有和没有该病家族史的未服用药物的精神分裂症患者之间,以及在精神分裂症患者的健康亲属和没有精神分裂症家族史的正常受试者之间,未发现显著差异。与基线值相比,氟哌啶醇治疗14天和21天后MAO活性显著降低。提示服用抗精神病药物可能至少部分解释了精神分裂症患者反复报告的低MAO值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验